Dr. Kevadiya's Lab

Research Goals
Techniques used in the lab
Return to Dr. Kevadiya's home page
Dr. Kevadiya's biographical information

Research Goals

  1. Development of long acting antiretroviral drugs tracking through molecular imaging technologies
  2. Development of on viral delivery and molecular imaging tracking system of CRISPR technology
  3. Monocyte-derived macrophages (MDMs) as drug delivery system-cell based vehicles for nanoparticle
  4. Development of virus like nanoparticles for targeting antiretroviral therapy and monitoring by nuclear medicine and molecular imaging technology
  5. Nano-cocrystal strategy for multi-drug antiretroviral therapy
  6. Synthesis of radiolabeled nanoparticles for nuclear medicine and molecular imaging technology for diagnostics as well as a therapeutic purpose


R01 MH121402-01A1                                                                         2019/12/01-2024/11/01

National Institute of Mental Health

HIV-1 Theranostic

The new field allows simultaneous detection (diagnostics) and treatment (therapeutic) for the identification and ultimate elimination of viral tissue compartments and cellular reservoir sites with a focus on the central nervous system. By employing theranostics viral entry sites in lymph nodes, gut and brain can be tracked during antiretroviral therapy (ART). Cellular viral targets including CD4+T cell populations and mononuclear phagocytes (MP; monocytes, macrophages, microglia and dendritic cells) subcellular endosomal structures can now be targeted for drug delivery in sites of active viral growth. The advantage of theranostics rests in that any steps towards improved HIV therapeutics and elimination strategies that requires precise targeted delivery of antiviral drugs. The long-term goal is to improve current therapeutic regimens with an emphasis on those that target the nervous system. This proposal seeks funds to accomplish this through improved HIV-1 drug monitoring, design of long acting, and gene editing technology to HIV-1 cure.

Role: MPI with Dash, P. and Gendelman, H.E.

P01 DA028555-06A1                         PI: Gendelman, Howard E.               2009/12/01-2020/06/30

National Institute on Drug Abuse (NIDA)

NanoART Manufacture, Delivery and Pharmacokinetics for Optimizing Drug Adherence

This is an integrative cross approach translational and multi-investigator program grant seeking to develop nanoformulated antiretroviral drug therapy from the bench to the patient.

Potential Overlap: This P01 proposal provides an infrastructure for producing nanomedicines. The medicines being developed in the two grants are distinct, the modifications not related and the encasements requiring very different approaches.

Role: Co-I

COVID-19 Rapid Response Grants PI: St Patrick Reid                    6/1/20 – 5/31/21

UNMC Nebraska Neuroscience Alliance

SARS-CoV-2-Macrophage Interactions for COVID-19 Neuropathobiology

The study of COVID-19 neuropathobiology allows us to characterize the human monocyte-macrophage-virus interactions linked to cell differentiation, activation, communication and bioactive factor secretion. We will decipher specific viral receptor regulations, cell signaling, epigenetic factor networks, inflammasome and each and all of their influences on contiguous neural vitality during the course of SARS-Cov-2 infection as a model system for CNS viral disease.

Role: Co-I


Dr. Kevadiya's home page
Dr. Kevadiya's biographical information